Recent development of antitumor agents from Chinese herbal medicines. Part II. High molecular compounds

Planta Medica

Volumn 69, Issue 3, 2003, Pages 193-201

  Tang, Weici ^a   Hemm, Ingrid ^a   Bertram, Barbara ^b  

^a Rheinland Pfälzische Technische Universität Kaiserslautern Landau   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Antitumor agents; Chinese herbal medicines; High molecular natural compounds

Indexed keywords

ANTINEOPLASTIC AGENT; ARMILLARIELLA TABESCENS EXTRACT; ASTRAGALUS MEMBRANACEUS EXTRACT; AURICULARIA AURICULA EXTRACT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DOXIFLURIDINE; FLUOROURACIL; GANODERMA LUCIDUM EXTRACT; HERBACEOUS AGENT; IMMUNOTOXIN; INTERLEUKIN 2; KRESTIN; LENTINAN; LUFFA CYLINDRICA EXTRACT; LYCIUM BARBARUM EXTRACT; MOMORDICA COCHINCHINENSIS; PEPTIDE DERIVATIVE; PHYTOLACCA AMERICANA EXTRACT; POLYSACCHARIDE; POLYSACCHARIDE PEPTIDE; PORIA COCOS EXTRACT; RIBOSOME INACTIVATING PROTEIN; TEGAFUR; TREMELLA FUSIFORMIS EXTRACT; TRICHOSANTHIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHINESE MEDICINE; CLINICAL TRIAL; CODONOPSIS; CODONOPSIS PILOSULA; COLON CARCINOMA; CYTOTOXICITY; DRUG CONJUGATION; DRUG ISOLATION; DRUG SYNTHESIS; DRUG TARGETING; EDIBLE MUSHROOM; FRUIT; FUNGUS; HUMAN; HYDATIDIFORM MOLE; IMMUNOSTIMULATION; LUFFA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULAR WEIGHT; MOMORDICA; NONHUMAN; PLANT; STOMACH CANCER; TRADITIONAL MEDICINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUGS, CHINESE HERBAL; HUMANS; MOLECULAR WEIGHT; PHYTOTHERAPY; PLANT PROTEINS; POLYSACCHARIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

ARMILLARIELLA TABESCENS; ASTRAGALI; ASTRAGALUS MEMBRANACEUS; AURICULA; AURICULARIA AURICULA-JUDAE; BASIDIOMYCOTA; COCOS; CODONOPSIS; CODONOPSIS PILOSULA; FRUCTUS; FUNGI; GANODERMA LUCIDUM; LUFFA; LUFFA CYLINDRICA; LYCIUM BARBARUM; MOMORDICA; MOMORDICA COCHINCHINENSIS; PHYTOLACCA AMERICANA; PORIA COCOS; RADIX ASTRAGALI; TREMELLA;

EID: 0037363703     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-38494     Document Type: Article

References (140)

1. Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev 2000; 5: 4-27
2. Ooi VE, Liu F. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curt Med Chem 2000; 7: 715-29
3. Chihara G, Hamuro J, Maeda Y, Arai Y, Fukuoka F. Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from Lentinus edodes (Berk.) Sing. (an edible mushroom). Cancer Res 1970; 30: 2776-81
4. Shida M, Ushioda Y, Nakajima T, Matsuda K. Structure of the alkali-insoluble skeletal glucan of Lentinus edodes. J Biochem (Tokyo) 1981; 90: 1093-100
5. Wang GL, Lin ZB. The immunomodulatory effect of lentinan. Acta Pharm Sin 1996; 31: 86-90
6. Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Hepatogastroenterology 1999; 46: 2662-8
7. Takita M, Onda M, Tokunaga A, Shirakawa T, Ikeda K, Hiramoto Y, et al. Successful treatment of hepatic metastasis of gastric cancer with 5′-DFUR and lentinan. Gan To Kagaku Ryoho 1998; 28: 129-33
8. Mio H, Terabe K. Clinical effects of postoperative immunochemotherapy with a combination of 5-FU, CDDP and lentinan for stage IVb gastric carcinoma and long-term pharmacokinetic studies on CDDP and 5-FU. Gan To Kagaku Ryoho 1997; 24: 337-42
9. Taguchi T. Clinical efficacy of lentinan on patients with stomach cancer: end point results of a four-year-follow-up survey. Cancer Detect Prev Suppl 1987; 1: 333-49
10. Takeshita K, Hayashi S, Tani M, Kando F, Saito N, Endo M. Monocyte function associated with intermittent lentinan therapy after resection of gastric cancer. Surg Oncol 1996; 5: 23-8
11. Arinaga S, Karimine N, Takamuku K, Nanbara S, Nagamatsu M, Ueo H, et al. Enhanced production of interleukin 1 and tumor necrosis factor by peripheral monocytes after lentinan administration in patients with gastric carcinoma. Int J Immunopharmacol 1992; 14: 43-7
12. Arinaga S, Karimine N, Takamuku K, Nanbara S, Inoue H, Nagamatsu M, et al. Enhanced induction of lymphokine-activated killer activity after lentinan administration in patients with gastric carcinoma. Int J Immunopharmacol 1992; 14: 535-9
13. Suto T, Fukuda S, Moriya N, Watanabe Y, Sasaki D, Yoshida Y, et al. Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma. Cancer Chemother Pharmacol 1994; 33 Suppl: 145-8
14. Chihara G. Preclinical evaluation of lentinan in animal models. Adv Exp Med Biol 1983; 166: 189-97
15. Li JF, Gun JW, Huang XF. Study on the enhancing effect of polyporus polysaccharide, mycobacterium polysaccharide and lentinan on lymphokine-activated killer cell activity in vitro. Chin J Integr Trad West Med 1996; 16: 224-6
16. Liu F, Ooi VE, Fung MC. Analysis of immunomodulating cytokine mRNAs in the mouse induced by mushroom polysaccharides. Life Sci 1999; 64: 1005-11
17. Ogawa T, Ohwada S, Sato Y, Izumi M, Nakamura S, Takeyoshi I, et al. Effects of 5′-DFUR and lentinan on cytokines and PyNPase against AH66 ascites hepatoma in rats. Anticancer Res 1999; 19A: 375-9
18. Murata T, Hatayama I, Kakizaki I, Satoh K, Sato K, Tsuchida S. Lentinan enhances sensitivity of mouse colon 26 tumor to cis-diamminedichloroplatinum (II) and decreases glutathione transferase expression. Jpn J Cancer Res 1996; 87: 1171-8
19. Haba S, Hamaoka T, Takatsu K, Kitagawa M. Selective suppression of T-cell activity in tumor-bearing mice and its improvement by lentinan, a potent anti-tumor polysaccharide. Int J Cancer 1976; 18: 93-104
20. Suzuki M, Takatsuki F, Maeda YY, Hamuro J, Chihara G. Antitumor and immunological activity of lentinan in comparison with LPS. Int J Immunopharmacol 1994; 16: 463-8
21. Mitamura T, Sakamoto S, Suzuki S, Yoshimura S, Maemura M, Kudo H. Effects of lentinan on colorectal carcinogenesis in mice with ulcerative colitis. Oncol Rep 2000; 7: 599-601
22. Oka M, Hazama S, Suzuki M, Wang F, Wadamori K, Iizuka N, et al. In vitro and in vivo analysis of human leukocyte binding by the antitumor polysaccharide, lentinan. Int J Immunopharmacol 1996; 18: 211-6
23. Ladanyi A, Timar J, Lapis K. Effect of lentinan on macrophage cytotoxicity against metastatic tumor cells. Cancer Immunol Immunother 1993; 36: 123-6
24. Jeannin JF, Lagadec P, Pelletier H, Reisser D, Olsson NO, Chihara G, et al. Regression induced by lentinan, of peritoneal carcinomatoses in a model of colon cancer in rat. Int J Immunopharmacol 1988; 10: 855-61
25. Morinaga H, Tazawa K, Tagoh H, Muraguchi A, Fujimaki M. An in vivo study of hepatic and splenic interleukin-1β mRNA expression following oral PSK or LEM administration. Jpn J Cancer Res 1994; 85: 1298-303
26. Suzuki M, Kikuchi T, Takatsuki F, Hamuro J. Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells. Cancer Immunol Immunother 1994; 38: 1-8
27. Moriyuki H, Ichimura M. Acute toxicity of lentinan in mice and rats. J Toxicol Sci 1980; 5 Suppl: 1-9
28. Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K. Krestin (PSK). Cancer Treat Rev 1984; 11: 131-55
29. Wang HX, NG TB, Liu WK, Ooi VE, Chang ST. Polysaccharide-peptide complexes from the cultured mycelia of the mushroom Coriolus versicolor and their culture medium activate mouse lymphocytes and macrophages. Int J Biochem Cell Biol 1996; 28: 601-7
30. Maehara Y, Inutsuka S, Takeuchi H, Baba H, Kusumoto H, Sugimachi K. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer Chemother Pharmacol 1993; 33 (2): 171-5
31. Kobayashi H, Matsunaga K, Fujii M. PSK as a chemopreventive agent. Cancer Epidemio Biomarkers Prev 1993; 2: 271-6
32. Fujii T, Saito K, Matsunaga K, Oguchi Y, Ikuzawa M, Furusho T, et al. Prolongation of the survival period with the biological response modifier PSK in rats bearing N-methyl-N-nitrosourea-induced mammary gland tumors. In Vivo 1995; 9: 55-7
33. Kobayashi Y, Kariya K, Saigenji K, Nakamura K. Suppression of cancer cell growth in vitro by the protein-bound polysaccharide of Coriolus versicolor Quel (PSK) with SOD mimicking activity. Cancer Biother 1994; 9: 63-9
34. Kobayashi Y, Kariya K, Saigenji K, Nakamura K. Enhancement of anticancer activity of cisdiaminedichloroplatinum by the protein-bound polysaccharide of Coriolus versicolor Quel (PSK) in vitro. Cancer Biother 1994; 9: 351-8
35. Sakagami H, Sugaya K, Utsumi A, Fujinaga S, Sato T, Takeda M. Stimulation by PSK of interleukin-1 production by human peripheral blood mononuclear cells. Anticancer Res 1993; 13: 671-5
36. Kohgo Y, Hirayama Y, Sakamaki S, Matsunaga T, Ohi S, Kuga T, et al. Improved recovery of myelosuppression following chemotherapy in mice by combined administration of PSK and various cytokines. Acta Haematol 1994; 92: 130-5
37. Kobayashi H, Matsunaga K, Oguchi Y. Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: an overview. Cancer Epidemio Biomarkers Prev 1995; 4: 275-81
38. Matsunaga K, Ohhara M, Oguchi Y, Iijima H, Kobayashi H. Antimetastatic effect of PSK, aprotein-bound polysaccharide, against the B16-BL6 mouse melanoma. Invasion and Metastasis 1996; 16: 27-38
39. Kanoh T, Matsunaga K, Saito K, Fujii T. Suppression of in vivo tumor-induced angiogenesis by the protein-bound polysaccharide PSK. In Vivo 1994; 8: 247-50
40. Pang ZJ, Chen Y, Zhou M, Wan J. Effect of polysaccharide krestin on glutathione peroxidase gene expression in mouse peritoneal macrophages. Br J Biomed Sci 2000; 57: 130-6
41. Pang ZJ, Chen Y, Zhou M. Polysaccharide Krestin enhances manganese superoxide dismutase activity and mRNA expression in mouse peritoneal macrophages. Am J Chin Med 2000; 28: 331-41
42. Asai K, Kato H, Hirose K, Akaogi K, Kimura S, Mukai S, et al. PSK and OK-432-induced immunomodulation of inducible nitric oxide (NO) synthase gene expression in mouse peritoneal polymorphonuclear leukocytes and NO-mediated cytotoxicity. Immunopharmacol Immunotoxicol 2000; 22: 221-35
43. Liu WK, Ng TB, Sze SF, Tsui KW. Activation of peritoneal macrophages by polysaccharopeptide from the mushroom, Coriolus versicolor. Immunopharmacology 1993; 26: 139-46
44. Qian ZM, Xu MF, Tang PL. Polysaccharide peptide (PSP) restores immunosuppression induced by cyclophosphamide in rats. Am J Chin Med 1997; 25: 27-35
45. Lin IH, Hau DM, Chang YH. Restorative effect of Coriolus versicolor polysaccharides against γ-irradiation-induced spleen injury in mice. Acta Pharmacol Sin 1996; 17: 102-4
46. Li XY, Wang JF, Zhu PP, Liu L, Ge JB, Yang SX. Immune enhancement of a polysaccharides peptides isolated from Coriolus versicolor. Acta Pharmacol Sin 1990; 11: 542-5
47. Mao XW, Archambeau JO, Gridley DS. Immunotherapy with low-dose interleukin-2 and a polysaccharopeptide derived from Coriolus versicolor. Cancer Biother Radiopharm 1996; 11: 393-403
48. Dong Y, Kwan CY, Chen ZN, Yang MM. Antitumor effects of a refined polysaccharide peptide fraction isolated from Coriolus versicolor: in vitro and in vivo studies. Res Commun Mol Pathol Pharmacol 1996; 92: 140-8
49. Misaki A, Kakuta M, Sasaki T, Tanaka M, Miyaji H. Studies on interrelation of structure and antitumor effects of polysaccharides: antitumor action of periodate-modified, branched (1→3)-β-D-glucan of Auricularia auricula-judae, and other polysaccharides containing (1→3)-glycosidic linkages. Carbohydr Res 1981; 92: 115-29
50. Kiho T, Shiose Y, Nagai K, Ukai S. Polysaccharides in fungi. XXX. Antitumor and immunomodulating activities of two polysaccharides from the fruiting bodies of Armillariella tabescens. Chem Pharm Bull (Tokyo) 1992; 40: 2110-4
51. Lee SS, Wei YH, Chen CF, Wang SY, Chen KY. Antineoplastic effects of Ganodermal ucidum. J Chin Med 1995; 6: 1-12
52. Li JE, Guo JW, Huang XF. Study on the enhancing effect of Polyporus polysaccharide, Mycobacterium polysaccharide and lentinan on lymphokine-activated killer cell activity in vitro Chin J Integr Trad West Med. 1996; 16: 224-6
53. Li JF, Huang XF, Lin BY. The effects on NK and endogenous LAK activities of splenic cells in mice by Polyporus polysaccharide in vivo. Chin J Microbiol Immunol 1995; 15: 89-91
54. Wu GS, Zhang LY, Okuda H. Inhibitive effect of Umbellatus polyporus polysaccharide on cachexic manifestation induced by toxohormone-L in rats. Chin J Integr Trad West Med 1997; 17: 232-3
55. Chihara G, Hamuro I, Maeda Y, Arai Y, Fukuoka F. Antitumor polysaccharide derived chemically from natural glucan (pachyman). Nature 1970; 225: 943-4
56. Kanayama H, Togami M, Adachi N, Fukai Y, Okumoto T. Studies on the antitumor active polysaccharides from the mycelia of Poria cocos Wolf. III. Antitumor activity against mouse tumors. Yakugaku Zasshi 1986; 106: 307-12
57. Gao QP, Jiang RZ, Chen HO, Jensen E, Seljelid R. Characterization and cytokine stimulating activities of heteroglycans from Tremella fuciformis. Planta Med 1996; 62: 297-302
58. Gao Q, Killie MK, Chen H, Jiang R, Seljelid R. Characterization and cytokine-stimulating activities of acidic heteroglycans from Tremella fuciformis. Planta Med 1997; 63: 457-60
59. Xia D, Lin ZB. Effects of Tremella polysaccharides on immune function in mice. Acta Pharmacol Sin 1989; 10: 453-7
60. Tomoda M, Shimizu N, Ohara N, Gonda R, Ishii S, Otsuki H. A reticuloendothelial system-activating glycan from the roots of Astragalus membranaceus. Phytochemistry 1991; 31: 63-6
61. Fang SD, Chen Y, Xu XY, Ye CQ, Zhai SK, Shen ML. Studies of the active principles of Astragalus mongholicus Bunge. I. Isolation, characterization and biological effect of its polysaccharides. Org Chem 1982: 26-31
62. Huang QS, Lu GB, Li YC, Guo JH, Wang RX. Studies on the polysaccharides of "Huang Qi" (Astragalus mongholicus Bunge). Acta Pharm Sin 1982; 17: 200-6
63. Shimizu N, Tomoda M, Kanari M, Gonda R. An acidic polysaccharide having activity on the reticuloendothelial system from the root of Astragalus mongholicus. Chem Pharm Bull (Tokyo) 1991; 39: 2969-72
64. Toshino S, Tabata T, Hazama SM, lizuka N, Yamamoto K, Hirayama M, et al. Immunoregulatory effects of the antitumor polysaccharide lentinan on Th1/Th2 balance in patients with digestive cancers. Anticancer Res 2000; 20C: 4707-11
65. Chang CY, Hou YD, Xu FM. Effects of Astragalus membranaceus on enhancement of mouse natural killer cell activity. Acta Acad Med Sin 1983; 5: 231-4
66. Tu WW, Yang YQ, Wang LJ, Zhang YW, Shen J. In vivo effects of Astragalus membranaceus on immunoglobulin G subclass deficiency. Chin J Immunol 1995; 11; 34-7
67. Wang DY, Li CY, Pong DW. Effect of Astrogalus polysaccharide on RNase and RNase inhibitor. Acta Biochem Biophys Sin 1984; 16: 285-90
68. Chu DT, Wong WL, Mavligit GM. Immunotherapy with Chinese medicinal herbs. II. Reversal of cyclophosphamide-induced immune suppression by administration of fractionated Astragalus membranaceus in vivo. J Chin Lab Immunol 1988; 25: 125-9
69. Chen LJ, Shen ML, Wang MY, Zhai SK, Liu MZ. Effect of Astragalus polysaccharides on phagocytic function in mice. Acta Pharmacol Sin 1981; 2: 200-4
70. Zhao KW, Kong HY. Effect of Astragalan on secretion of tumor necrosis factors in human peripheral blood mononuclear cells. Chin J Integr Trad West Med 1993; 13: 263-5, 259
71. Ma D, Cai GR, Liu CM. Inhibitory effect of Astragalus membranaceus and Acanthopanax senticosus on proliferation of human ovarian cancer cells in vitro. Tumor 1992; 12: 51-2
72. Lau BH, Ruckle HC, Botolazzo T, Lui PD. Chinese medicinal herbs inhibit growth of murine renal cell carcinoma. Cancer Biother 1994; 9: 153-61
73. Yang HX, Zhao G. Death and apoptosis of LAK cell during immunologic assault and the rescuing effects of APS. Chin J Clin Oncol 1998; 25: 669-72
74. Cha RJ, Zeng DW, Chang QS. Non-surgical treatment of small cell lung cancer with chemo-radio-immunotherapy and traditional Chinese medicine. Chin J Int Med 1994; 33: 462-6
75. Wang DC. Influence of Astragalus membranaceus (AM) polysaccharide FB on immunologic function of human periphery blood lymphocyte. Chin J Oncol 1989; 11: 180-3
76. Chu DT, Wong WL, Mavligit GM. Immunotherapy with Chinese medicinal herbs. I. Immune restoration of local xenogeneic graft-versus-host reaction in cancer patients by fractionated Astragalus membranaceus in vitro. J Chin Lab Immunol 1988; 25: 119-23
77. He J, Zhang SH. Isolation and composition of Lycium barbarum polysaccharides. Chin Pharm J (Beijing) 1996; 31: 716-20
78. Tian GY, Wang C. Structure elucidation of a high MW glycan of a glycoprotein isolated from the fruit of Lycium barbarum L. Acta Biochimica Biophysica Sinica 1995; 27: 493-8
79. Zhao CJ, He YQ, Li RZ, Cui GH. Chemistry and pharmacological activtiy of peptidoglycan from Lycium barbarum. Chin Chem Lett 1996; 7: 1009-10
80. Gan L, Zhang S. Determination of four fractions of Lycium barbarum polysaccharides in different varieties. J Chin Med Mater 2001; 24: 107-8
81. Du SY, Qian YK. Effect of extract of Lycium barbarum on the IL-2R expression of humen lymphocytes. Chin J Microbiol Immunol 1995; 15: 176-8
82. Sun WJ, Sui DY, Yu XF, Lu ZZ, Hou CZ. Pharmacological studies of polysaccharide-proteins from Lycium barbarum. J Norman Bethune Univ Med Sci 1996; 22: 486-7
83. Geng CS, Xing ST, Zhou JH, Chu BM. Enhancing effect of Lycium barbarum polysaccharides on the interleukin-2 activity in mice. Chin J Pharmacol Toxicol 1989; 3: 175-9
84. Zhang X, Li J, Liang HB, Wang L, Qian YK. Effects of Lycium barbarum polysaccharide on the cell membrane fruidity and protein kinase C in vitro. J Beijing Med Univ 1997; 29: 118-20
85. Zhang X, Xiang SL, Cui XY, Qian YK. Effects of Lycium barbarum polysaccharide (LBP) on lymphocyte signal transduction system in mice. Chin J Immunol 1997; 13: 289-92
86. 3H]thymidine incorporation into splenic lymphocytes and on suppressor T-lymphocytes in mice. Chin Trad Herbal Drugs 1988; 19: 313-5
87. Cao GW, Du P. Influence of Lycium barbarum polysaccharides and interleukin-2 in vivo on the induction of two kinds of LAK cells from aged mice in vitro. Chin J Microbiol Immunol 1992; 12: 390-2
88. Wang BX, Xing ST, Zhou JH. Effect of Lycium barbarum polysaccharides on the immune responses of T, CTL and NK cells in normal and cyclophosphamide-treated mice. Chin J Pharmacol Toxicol 1990; 4: 39-43
89. Cao GW, Yang WG, Du P. Observation of the effects of LAK/IL-2 therapy combining with Lycium barbarum polysaccharides in the treatment of 75 cancer patients. Chin J Oncol 1994; 16: 428-31
90. Liu JN, Cheng BQ, Zhang JR, Tan XR, Ji YZ. Effect of Lycium polysaccharide on immune responses of cancer patients following radiotherapy. Zhonghua Fangshe Yixue Yu Fanghu Zazhi 1996; 16: 18-20
91. Sun WJ, Xu WL, Zhang YX, Huang RH, Duan GS. Therapeutic effects of Lycium barbarum polysaccharides in combination with irradiation and carmustine in G422 tumor-bearing mice. Chin J Clin Oncol 1994; 21: 930-2
92. Lu CX, Cheng BQ. Radiosensitizing effects of Lycium barbarum polysaccharide for Lewis lung cancer. Chin J Integr Trad West Med 1991; 11: 611-2
93. Liu JL, Zhang LH, Qian YK. Tumor inhibition of Lycium barbarum polysaccharide on S180-bearing mice. Chin J Immunol 1996; 12: 115-7
94. Zhang SJ, Zhang SY. Polysaccharides of Dangshen (Codonopsis pilosula). Chin Trad Herbal Drugs 1987; 18: 98-100
95. Shun BE, Yoshida Y, Sugiura T, Yamashita U. Stimulating activity of Chinese medicinal herbs on human lymphocytes in vitro. Int J Immunopharmacol 1999; 21: 149-59
96. Mao XL, Zhou Y. Preliminary study of the effects of extract of Codonopsis pilosula on immunological functions of normal and immunosuppressed mice introduced by cyclophosphamide. Chin J Integr Trad West Med 1985; 5: 739-41
97. Hu SK. Effect of the combination of Codonopsis pilosula and cyclophosphamide on the transplantable tumor and tumor-bearing mice. Chin J Integr Trad West Med 1985; 5: 618-21
98. Zeng XL, Li XA, Zhang BY. Immunological and hematopoietic effect of Codonopsis pilosula on cancer patients during radiotherapy. Chin J Integr Trad West Med 1992; 12: 607-8,581
99. Wang RH, Zhang S, Chen X, Shen BF. Inhibition of protein synthesis in cell-free system by single chain ribosome-inactivating proteins. Chin Biochem J 1992; 8: 395-9
100. Wang Y, Gu ZW, Ye GJ, Sun XJ, Wang QH, Jin SW. Revision of the primary structure of trichosanthin and study on the trichosanthin from different places of origin. Acta Chim Sin 1993; 51: 1023-9
101. Wu TW, Pang KC, Wu CC, Wu HT, Chang YM, Ni CC, et al. Growth of single crystals and determination of unit-cell parameters for trichosanthin. Kexue Tongbao 1978; 23: 176-8
102. Dong TX, Ng TB, Yeung HW, Wong RNS. Isolation and characterization of a novel ribosome-inactivating protein, β-kirilowin, from the seeds of Trichosanthes kirilowii. Biochem Biophys Res Commun 1994; 199: 387-93
103. Wong RNS, Dong TX, Ng TB, Choi WT, Yeung HW. α-Kirilowin, a novel ribosome-inactivating protein from seeds of Trichosanthes kirilowii (family Cucurbitaceae): a comparison with β-kirilowin and other related proteins. Int J Pept Protein Res 1996; 47: 103-9
104. Gu Y, Chen W, Xia Z. Molecular modeling of the interactions of trichosanthin with four substrate analogs. J Protein Chem 2000; 19: 291-7
105. Gu YJ, Xia ZX. Crystal structures of the complexes of trichosanthin with four substrate analogs and catalytic mechanism of RNA N-glycosidase. Proteins 2000; 39: 37-46
106. Nie H, Cai X, He X, Xu L, Ke K, Ke Y, et al. Position 120-123, a potential active site of trichosanthin. Life Sci 1998; 62: 491-500
107. Xi ZD, Ma BL, Yang LM, Cao HN, Wang M. Active site of trichosanthin acting as a ribosome-inactivating protein. Acta Pharmacol Sin 1997; 18: 447-51
108. Mulot S, Chung KK, Li XB, Wong CC, Ng TB, Shaw PC. The antigenic sites of trichosanthin a ribosome-inactivating protein with multiple pharmacological properties. Life Sci 1997; 61: 2291-303
109. Shaw PC, Chan WL, Yeung HW, Ng TB. Minireview: trichosanthin - a protein with multiple pharmacological properties. Life Sci 1994; 55: 253-62
110. Takemoto DJ. Effect of trichosanthin, an anti-leukemia protein on normal mouse spleen cells. Anticancer Res 1998; 18(A): 357-61
111. Lu PX, Jin YC. Trichosanthin in the treatment of hydatidiform mole. Clinical analysis of 52 cases Chin Med J (Engl Ed) 1990; 103: 183-5
112. Zhang CY, Gong YX, Ma H, An CC, Chen DY. Trichosanthin induced calcium-dependent generation of reactive oxygen species in human choriocarcinoma cells. Analyst 2000; 125: 1539-42
113. Ru QH, Luo GA, Liao JJ, Liu Y. Capillary electrophoretic determination of apoptosis of HeLa cells induced by trichosanthin. J Chromatogr A 2000; 894: 165-70
114. Zhang RP, Xu CJ, Cao HT, Ji RH, Zhang ZC. In vitro inhibition of trichosanthin-conjugate on human melanoma cells. Chin J Immunol 1993; 9: 348-51
115. Wang QC, Ying WB, Xie H, Zhang ZC, Yang ZH, Ling LQ. Trichosanthin-monoclonal antibody conjugate specifically cytotoxic to human hepatoma cells in vitro. Cancer Res 1991; 51: 3353-5
116. Gao HL, Zhou GY, Lu DY, Zhang WY. Trichosanthin - CEA Mab conjugate cytotoxic to human colon carcinoma. Chin J Immunol 1992; 8: 300-3
117. Islam MR, Nishida H, Funatsu G. Complete amino acid sequence of luffin-α, a ribosome-inactivating protein from the seeds of Luffa cylindrica. Agric Biol Chem 1990; 54: 1343-5
118. Chen RS, Leung HW, Dong YC, Wong RN. Modeling of the three-dimensional structure of luffin-α and its stimulated reaction with the substrate oligoribonucleotide GAGA. J Protein Chem 1996; 15: 649-57
119. Kataoka J, Habuka N, Miyano M, Masuta C, Koiwai A. Nucleotide sequence of cDNA encoding β-luffin, another ribosome-inactivating protein from Luffa cylindrica. Plant Mol Biol 1993; 19: 887-9
120. Gao W, Ling J, Zhong X, Liu W, Zhang R, Yang H, et al. Luffin-S: a small novel ribosome-inactivating protein from Luffa cylindrica. Characterization and mechanism studies. FEBS Lett 1994; 347: 257-60
121. Ng TB, Chan WY, Yeung HW. Proteins with abortifacient, ribosome inactivating, immunomodulatory, antitumor and anti-AIDS activities from Cucurbitaceae plants. Gen Pharmacol 1992; 23: 579-90
122. Poma A, Marcozzi G, Cesare P, Carmignani M, Spano L. Antiproliferative effect and apoptotic resonse in vitro of human melanoma cells to liposomes containing the ribosome-inactivating protein luffin. Biochim Biophys Acta 1999; 1472: 197-205
123. Poma A, Miranda M, Spano L. Differential response of human melanoma and Ehrlich ascites cells in vitro to the ribosome-inactivating protein luffin. Melanoma Res 1998; 8: 465-7
124. Huang B, Ng TB, Fong WP, Wan CC, Yeung HW. Isolation of a trypsin inhibitor with deletion of N-terminal pentapeptide from the seeds of Momordica cochinchinensis, the Chinese drug mubiezhi. Int J Biochem Cell Biol 1999; 31: 707-15
125. Hernandez JF, Gagnon J, Chiche L, Nguyen TM, Andrieu JP, Heitz A, et al. Squash trypsin inhibitors from Momordica cochinchinensis exhibit an atypical macrocyclic structure. Biochemistry 2000; 39: 5722-30
126. Zhang AH, Tang S, Liu W. Substrate-structure dependence of ribotoxins on cleaving RNA in C. camphora ribosome. J Nat Toxins 2001; 10: 119-25
127. 1H-nuclear magnetic resonance. Biol Chem 2000; 381: 447-51
128. Ruan JP, Chen WF, Liu WY. Promotion of ATP and S-140 to ribosome inactivation with camphorin, cinnamomin, and other RNA N-glycosidases. Acta Pharmacol Sin 1998; 19: 261-4
129. Li XD, Chen WF, Liu WY, Wang GH. Large-scale preparation of two new ribosome-inactivating proteins-cinnamomin and camphorin from the seeds of Cinnamomum camphora. Protein Expr Purif 1997; 10: 27-31
130. Kurinov IV, Mao C, Irvin JD, Uckun FM. X-ray crystallographic analysis of pokeweed antiviral protein-II after reductive methylation of lysine residues. Biochem Biophys Res Commun 2000; 275: 549-52
131. Ferens WA, Hovde CJ. Antiviral activity of shiga toxin 1: suppression of bovine leukemia virus-related spontaneous lymphocyte proliferation. Infect Immun 2000; 68: 4462-9
132. Schlick J, Dulieu P, Desvoyes B, Adami P, Radom J, Jouvenot M. Cytotoxic activity of a recombinant GnRH-PAP fusion toxin on human tumor cell lines. FEBS Lett 2000; 472: 241-6
133. Waurzyniak B, Schneider EA, Turner N, Yanishevski Y, Gunther R, Chelstrom LM, et al. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. Clin Cancer Res 1997; 3: 881-90
134. Zhong RK, van De Winkel JG, Thepen T, Schultz LD, Ball ED. Cytotoxicity of anti-cd64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in scid mice. J Hematother Stem Cell Res 2001; 10: 95-105
135. van Oosterhout YV, van Ernst JL, Bakker HH, Preijers FW, Schattenberg AV, Ruiter DJ, et al. Production of anti-CD3 and anti-CD7 ricin A-immunotoxins for a clinical pilot study. Int J Pharm 2001; 221: 175-86
136. Schindler J, Sausville E, Messmann R, Uhr JW, Vitetta ES. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. Clin Cancer Res 2001; 7: 255-8
137. Longo DL, Duffey PL, Gribben JG, Jaffe ES, Curti BD, Gause BL, et al. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study. Cancer J Sci Am 2000; 6: 146-50
138. Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, Figg WD, Schindler J, et al. A phase 1 study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin Cancer Res 2000; 6: 1302-13
139. Schnell R, Vitetta E, Schindler J, Borchmann P, Barth S, Ghetie V, et al. Treatment fo refractory Hodgkin's lymphoma patients with an anti-CD25 rich A-chain immunotoxin. Leukemia 2000; 14: 129-35
140. Grossbard ML, Multani PS, Freedman AS, O'Day S, Gribben JG, Rhuda C, et al. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res 1999; 5: 2392-8